publication venue for
- Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis.. ahead-of-print:1-7. 2024
- Epicutaneous Immunotherapy with Viaskin Peanut in toddlers: a plain language summary. 16:5-13. 2024
- Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma. 15:819-826. 2023
- Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors. 14:777-787. 2022
- No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors. 14:765-776. 2022
- Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors. 14:23-30. 2022
- Multicenter Real-World Experience with Epinephrine 0.5 mg Dosing for Anaphylaxis with Allergen Immunotherapy. 13:1325-1331. 2021
- A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis. 13:477-481. 2021
- Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma. 13:217-225. 2021
- Romosozumab in the Treatment of Osteoporosis. 12:965-981. 2020
- Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy. 12:785-798. 2020
- Systemic Therapy for Previously Untreated Advanced BRAF -Mutated Melanoma: Navigating a Shifting Landscape. 9:375-378. 2017
- Tumor-Targeting Domains for Chimeric Antigen Receptor T Cells. 9:33-46. 2017
- Erratum. 6:657-658. 2014
- Evolution of oncolytic viruses: novel strategies for cancer treatment (vol 5, pg 1191, 2013). 6:657-658. 2014
- Evolution of Oncolytic Viruses: Novel Strategies for Cancer Treatment. 5:1191-1206. 2013